Literature DB >> 25667445

Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer.

Kenji Sugano1, Kiyoshi Maeda2, Hiroshi Ohtani1, Hisashi Nagahara1, Masatsune Shibutani1, Kosei Hirakawa1.   

Abstract

BACKGROUND: The function of a cysteine-glutamate exchanger (xCT) transporter is to increase the intracellular concentration of glutathione in order to protect cells from oxidative stress. In several types of cancer, xCT is thought to play a role in the onset of resistance to chemotherapy and radiotherapy. xCT is stabilized on the tumor cell surface after combining with cluster of differentiation 44 variant (CD44v).
MATERIALS AND METHODS: We examined the xCT and CD44v6 expression in 304 primary tumor samples obtained from patients with colorectal cancer using immunohistochemical analysis.
RESULTS: Immunoreactivity for xCT was observed in 208 (68.4%) tumors. Among 218 patients with stage I-III disease who underwent curative surgery, the postoperative recurrence rate was 32.9% in those with xCT-positive tumors, which was significantly (p=0.003) higher than in those with xCT-negative tumors (10.7%). Immunoreactivity for CD44v6 was observed in 101 cases (33.2%), although the rate of postoperative recurrence in patients with CD44v6-positive tumors did not exhibit any significant correlation. Multivariate analyses revealed increased xCT expression to be an independent significant predictor of disease recurrence, in addition to depth of tumor invasion, lymph node metastasis and venous invasion. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CD44v6; CRC; colorectal cancer; immunohistochemistry; recurrence; xCT

Mesh:

Substances:

Year:  2015        PMID: 25667445

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  21 in total

1.  In silico characterization of residues essential for substrate binding of human cystine transporter, xCT.

Authors:  Monika Sharma; C R Anirudh
Journal:  J Mol Model       Date:  2019-11-09       Impact factor: 1.810

2.  Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer.

Authors:  Yasuhito Iseki; Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tetsuro Ikeya; Kosei Hirakawa
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

3.  Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.

Authors:  Gaetano Donofrio; Giulia Tebaldi; Stefania Lanzardo; Roberto Ruiu; Elisabetta Bolli; Andrea Ballatore; Valeria Rolih; Francesca Macchi; Laura Conti; Federica Cavallo
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

4.  SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma.

Authors:  Hayato Baba; Mitsuro Kanda; Koichi Sawaki; Shunsuke Nakamura; Sei Ueda; Dai Shimizu; Masahiko Koike; Yasuhiro Kodera; Tsutomu Fujii
Journal:  Ann Surg Oncol       Date:  2021-11-12       Impact factor: 5.344

Review 5.  Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer.

Authors:  Xuan Liu; Yiqian Zhang; Xuyi Wu; Fuyan Xu; Hongbo Ma; Mengling Wu; Yong Xia
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

Review 6.  xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.

Authors:  Jinyun Liu; Xiaojun Xia; Peng Huang
Journal:  Mol Ther       Date:  2020-09-02       Impact factor: 11.454

7.  xCT/SLC7A11 antiporter function inhibits HIV-1 infection.

Authors:  Jesse Rabinowitz; Hamayun J Sharifi; Hunter Martin; Anthony Marchese; Michael Robek; Binshan Shi; Alexander A Mongin; Carlos M C de Noronha
Journal:  Virology       Date:  2021-01-20       Impact factor: 3.616

Review 8.  System Xc-: a key regulatory target of ferroptosis in cancer.

Authors:  Man-Ru Liu; Wen-Tao Zhu; Dong-Sheng Pei
Journal:  Invest New Drugs       Date:  2021-01-27       Impact factor: 3.850

Review 9.  The metabolism of cancer cells during metastasis.

Authors:  Gabriele Bergers; Sarah-Maria Fendt
Journal:  Nat Rev Cancer       Date:  2021-01-18       Impact factor: 60.716

10.  xCT contributes to colorectal cancer tumorigenesis through upregulation of the MELK oncogene and activation of the AKT/mTOR cascade.

Authors:  Bufu Tang; Jinyu Zhu; Fangming Liu; Jiayi Ding; Yajie Wang; Shiji Fang; Liyun Zheng; Rongfang Qiu; Minjiang Chen; Gaofeng Shu; Min Xu; Chenying Lu; Zhongwei Zhao; Yang Yang; Jiansong Ji
Journal:  Cell Death Dis       Date:  2022-04-19       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.